View Item 

Show simple item record

Protecting the Kidney in Liver Transplant Recipients: Practice‐Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice
dc.contributor.authorLevitsky, J.
dc.contributor.authorO’Leary, J. G.
dc.contributor.authorAsrani, S.
dc.contributor.authorSharma, P.
dc.contributor.authorFung, J.
dc.contributor.authorWiseman, A.
dc.contributor.authorNiemann, C. U.
dc.date.accessioned2016-10-17T21:17:47Z
dc.date.available2017-11-01T15:31:29Zen
dc.date.issued2016-09
dc.identifier.citationLevitsky, J.; O’Leary, J. G.; Asrani, S.; Sharma, P.; Fung, J.; Wiseman, A.; Niemann, C. U. (2016). "Protecting the Kidney in Liver Transplant Recipients: Practice‐Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice." American Journal of Transplantation 16(9): 2532-2544.
dc.identifier.issn1600-6135
dc.identifier.issn1600-6143
dc.identifier.urihttps://hdl.handle.net/2027.42/134132
dc.publisherWiley Periodicals, Inc.
dc.subject.otherclinical research/practice
dc.subject.otherimmunosuppressive regimens
dc.subject.othermaintenance
dc.subject.otherkidney (native) function/dysfunction
dc.subject.othercomplication: medical/metabolic
dc.subject.otherliver allograft function/dysfunction
dc.subject.otherimmunosuppression/immune modulation
dc.subject.otherglomerular filtration rate (GFR)
dc.subject.otherkidney transplantation/nephrology
dc.subject.otherliver transplantation/hepatology
dc.subject.othertranslational research/science
dc.titleProtecting the Kidney in Liver Transplant Recipients: Practice‐Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134132/1/ajt13765_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134132/2/ajt13765.pdf
dc.identifier.doi10.1111/ajt.13765
dc.identifier.sourceAmerican Journal of Transplantation
dc.identifier.citedreferenceJames PA, Oparil S, Carter BL, et al. 2014 evidence‐based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507 – 520.
dc.identifier.citedreferenceNajeed SA, Saghir S, Hein B, et al. Management of hypertension in liver transplant patients. Int J Cardiol 2011; 152: 4 – 6.
dc.identifier.citedreferenceMidtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared with lisinopril. Transplantation 2001; 72: 1787 – 1792.
dc.identifier.citedreferenceMourad G, Ribstein J, Mimran A. Converting‐enzyme inhibitor versus calcium antagonist in cyclosporine‐treated renal transplants. Kidney Int 1993; 43: 419 – 425.
dc.identifier.citedreferenceJones‐Burton C, Mishra SI, Fink JC, et al. An in‐depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 2006; 26: 268 – 275.
dc.identifier.citedreferenceFouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009; CD001892.
dc.identifier.citedreferenceRobertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007; CD002181.
dc.identifier.citedreferenceLoniewski I, Wesson DE. Bicarbonate therapy for prevention of chronic kidney disease progression. Kidney Int 2014; 85: 529 – 535.
dc.identifier.citedreferenceZoungas S, Ninomiya T, Huxley R, et al. Systematic review: Sodium bicarbonate treatment regimens for the prevention of contrast‐induced nephropathy. Ann Intern Med 2009; 151: 631 – 638.
dc.identifier.citedreferenceVaitkus PT, Brar C. N‐acetylcysteine in the prevention of contrast‐induced nephropathy: Publication bias perpetuated by meta‐analyses. Am Heart J 2007; 153: 275 – 280.
dc.identifier.citedreferenceSaidman SL, Duquesnoy RJ, Demetris AJ, et al. Combined liver‐kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994; 2: 61 – 67.
dc.identifier.citedreferenceNeumann UP, Lang M, Moldenhauer A, et al. Significance of a T‐lymphocytotoxic crossmatch in liver and combined liver‐kidney transplantation. Transplantation 2001; 71: 1163 – 1168.
dc.identifier.citedreferenceAskar M, Schold JD, Eghtesad B, et al. Combined liver‐kidney transplants: Allosensitization and recipient outcomes. Transplantation 2011; 91: 1286 – 1292.
dc.identifier.citedreferenceFung J, Makowka L, Tzakis A, et al. Combined liver‐kidney transplantation: Analysis of patients with preformed lymphocytotoxic antibodies. Transpl Proc 1988; 20 ( 1 Suppl 1 ): 88 – 91.
dc.identifier.citedreferenceOlausson M, Mjornstedt L, Norden G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross‐match positive recipients. Am J Transplant 2007; 7: 130 – 136.
dc.identifier.citedreferenceDar W, Agarwal A, Watkins C, et al. Donor‐directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841 – 847.
dc.identifier.citedreferenceKatznelson S, Cecka JM. The liver neither protects the kidney from rejection nor improves kidney graft survival after combined liver and kidney transplantation from the same donor. Transplantation 1996; 61: 1403 – 1405.
dc.identifier.citedreferenceEid A, Moore SB, Wiesner RH, DeGoey SR, Nielson A, Krom RA. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver‐kidney transplantation across a positive lymphocyte crossmatch. Transplantation 1990; 50: 331 – 334.
dc.identifier.citedreferenceStarzl TE, Demetris AJ, Todo S, et al. Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant 1989; 3: 37 – 45.
dc.identifier.citedreferenceO’Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver‐kidney transplantation. Am J Transplant 2013; 13: 954 – 960.
dc.identifier.citedreferenceO’Leary JG, Demetris AJ, Friedman LS, et al. The role of donor‐specific HLA alloantibodies in liver transplantation. Am J Transplant 2014; 14: 779 – 787.
dc.identifier.citedreferenceNilles KM, Krupp J, Lapin B, Sustento‐Reodica N, Gallon L, Levitsky J. Incidence and impact of rejection following simultaneous liver‐kidney transplantation. J Hepatol 2015; 62: 340 – 345.
dc.identifier.citedreferenceO’Leary JG, Cai J, Freeman R, et al. Proposed diagnostic criteria for chronic antibody‐mediated rejection in liver allografts. Am J Transplant 2016; 16: 603 – 614.
dc.identifier.citedreferenceO’Leary JG, Samaniego M, Barrio MC, et al. The influence of immunosuppressive agents on the risk of de novo donor‐specific HLA antibody production in solid organ transplant recipients. Transplantation 2016; 100: 39 – 53.
dc.identifier.citedreferenceTaner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor‐specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504 – 1510.
dc.identifier.citedreferenceKaneku H, O’Leary JG, Banuelos N, et al. De novo donor‐specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013; 13: 1541 – 1548.
dc.identifier.citedreferenceBiancofiore G, Pucci L, Cerutti E, et al. Cystatin C as a marker of renal function immediately after liver transplantation. Liver Transpl 2006; 12: 285 – 291.
dc.identifier.citedreferenceLing Q, Xu X, Li JJ, Chen J, Shen JW, Zheng SS. Alternative definition of acute kidney injury following liver transplantation: Based on serum creatinine and cystatin C levels. Transpl Proc 2007; 39: 3257 – 3260.
dc.identifier.citedreferenceLing Q, Xu X, Li J, et al. A new serum cystatin C‐based equation for assessing glomerular filtration rate in liver transplantation. Clin Chem Lab Med 2008; 46: 405 – 410.
dc.identifier.citedreferenceGerhardt T, Poge U, Stoffel‐Wagner B, et al. Estimation of glomerular filtration rates after orthotopic liver transplantation: Evaluation of cystatin C‐based equations. Liver Transpl 2006; 12: 1667 – 1672.
dc.identifier.citedreferenceLevitsky J, Salomon DR, Abecassis M, et al. Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation. Am J Transplant 2011; 11: 1972 – 1978.
dc.identifier.citedreferenceSharma P, Schaubel DE, Guidinger MK, Goodrich NP, Ojo AO, Merion RM. Impact of MELD‐based allocation on end‐stage renal disease after liver transplantation. Am J Transplant 2011; 11: 2372 – 2378.
dc.identifier.citedreferenceRuebner R, Goldberg D, Abt PL, et al. Risk of end‐stage renal disease among liver transplant recipients with pretransplant renal dysfunction. Am J Transplant 2012; 12: 2958 – 2965.
dc.identifier.citedreferenceHilmi IA, Damian D, Al‐Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: Incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth 2015; 114: 919 – 926.
dc.identifier.citedreferenceKlaus F, Keitel da Silva C, Meinerz G, et al. Acute kidney injury after liver transplantation: Incidence and mortality. Transpl Proc 2014; 46: 1819 – 1821.
dc.identifier.citedreferenceLeithead JA, Rajoriya N, Gunson BK, Muiesan P, Ferguson JW. The evolving use of higher risk grafts is associated with an increased incidence of acute kidney injury after liver transplantation. J Hepatol 2014; 60: 1180 – 1186.
dc.identifier.citedreferenceKarapanagiotou A, Dimitriadis C, Papadopoulos S, et al. Comparison of RIFLE and AKIN criteria in the evaluation of the frequency of acute kidney injury in post‐liver transplantation patients. Transpl Proc 2014; 46: 3222 – 3227.
dc.identifier.citedreferenceO’Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE criteria, post‐liver transplantation. Am J Transplant 2007; 7: 168 – 176.
dc.identifier.citedreferenceAllen AM, Kim WR, Therneau TM, Larson JJ, Heimbach JK, Rule AD. Chronic kidney disease and associated mortality after liver transplantation ‐ A time‐dependent analysis using measured glomerular filtration rate. J Hepatol 2014; 61: 286 – 292.
dc.identifier.citedreferenceSharma P, Goodrich NP, Schaubel DE, Guidinger MK, Merion RM. Patient‐specific prediction of ESRD after liver transplantation. J Am Soc Nephrol 2013; 24: 2045 – 2052.
dc.identifier.citedreferenceKim WR, Stock PG, Smith JM, et al. OPTN/SRTR 2011 Annual Data Report: Liver. Am J Transplant 2013; 13 ( Suppl 1 ): 73 – 102.
dc.identifier.citedreferenceOjo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931 – 940.
dc.identifier.citedreferenceSharma P, Schaubel DE, Guidinger MK, Merion RM. Effect of pretransplant serum creatinine on the survival benefit of liver transplantation. Liver Transpl 2009; 15: 1808 – 1813.
dc.identifier.citedreferenceEason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008; 8: 2243 – 2251.
dc.identifier.citedreferenceNadim MK, Sung RS, Davis CL, et al. Simultaneous liver‐kidney transplantation summit: Current state and future directions. Am J Transplant 2012; 12: 2901 – 2908.
dc.identifier.citedreferenceAllen AM, Kim WR, Larson JJ, Colby C, Therneau TM, Rule AD. Serum cystatin C as an indicator of renal function and mortality in liver transplant recipients. Transplantation 2015; 99: 1431 – 1435.
dc.identifier.citedreferenceAsrani SK, Kim WR, Heimbach JH, et al. Acute tubular necrosis is present in the majority of patients undergoing liver transplantation. Hepatology 2011; 54 ( S1 ): 159A.
dc.identifier.citedreferenceWadei HM, Heckman MG, Rawal B, et al. Renal outcomes of liver transplant recipients who had pretransplant kidney biopsy. Transplantation 2014; 98: 1323 – 1330.
dc.identifier.citedreferenceAtkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004; 4: 38.
dc.identifier.citedreferenceCholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007; 13: 523 – 529.
dc.identifier.citedreferenceShaffi K, Uhlig K, Perrone RD, et al. Performance of creatinine‐based GFR estimating equations in solid‐organ transplant recipients. Am J Kidney Dis 2014; 63: 1007 – 1018.
dc.identifier.citedreferenceDe Souza V, Hadj‐Aissa A, Dolomanova O, et al. Creatinine‐ versus cystatine C‐based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 2014; 59: 1522 – 1531.
dc.identifier.citedreferenceShlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369: 932 – 943.
dc.identifier.citedreferenceInker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20 – 29.
dc.identifier.citedreferenceLevey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604 – 612.
dc.identifier.citedreferenceLeithead JA, Ferguson JW. Chronic kidney disease after liver transplantation. J Hepatol 2015; 62: 243 – 244.
dc.identifier.citedreferenceLevitsky J, Baker T, Ahya SN, et al. Outcomes and native renal recovery following simultaneous liver‐kidney transplantation. Am J Transplant 2012; 12: 2949 – 2957.
dc.identifier.citedreferenceVagefi PA, Qian JJ, Carlson DM, et al. Native renal function after combined liver‐kidney transplant for type 1 hepatorenal syndrome: Initial report on the use of postoperative Technetium‐99 m‐mercaptoacetyltriglycine scans. Transpl Int 2013; 26: 471 – 476.
dc.identifier.citedreferenceCabezuelo JB, Ramirez P, Rios A, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69: 1073 – 1080.
dc.identifier.citedreferenceHilmi IA, Peng Z, Planinsic RM, et al. N‐acetylcysteine does not prevent hepatorenal ischaemia‐reperfusion injury in patients undergoing orthotopic liver transplantation. Nephrol Dial Transplant 2010; 25: 2328 – 2333.
dc.identifier.citedreferenceDella Rocca G, Pompei L, Costa MG, et al. Fenoldopam mesylate and renal function in patients undergoing liver transplantation: A randomized, controlled pilot trial. Anesth Analg 2004; 99: 1604 – 1609, table of contents.
dc.identifier.citedreferenceBiancofiore G, Della Rocca G, Bindi L, et al. Use of fenoldopam to control renal dysfunction early after liver transplantation. Liver Transpl 2004; 10: 986 – 992.
dc.identifier.citedreferenceHand WR, Whiteley JR, Epperson TI, et al. Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: A single‐center retrospective review. Anesth Analg 2015; 120: 619 – 626.
dc.identifier.citedreferenceNadeem A, Salahuddin N, El Hazmi A, et al. Chloride‐liberal fluids are associated with acute kidney injury after liver transplantation. Crit Care 2014; 18: 625.
dc.identifier.citedreferenceMukhtar A, Aboulfetouh F, Obayah G, et al. The safety of modern hydroxyethyl starch in living donor liver transplantation: A comparison with human albumin. Anesth Analg 2009; 109: 924 – 930.
dc.identifier.citedreferencePillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005; 5: 1120 – 1129.
dc.identifier.citedreferenceNiemann CU, Walia A, Waldman J, et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase‐associated lipocalin. Liver Transpl 2009; 15: 1852 – 1860.
dc.identifier.citedreferenceGrande L, Rimola A, Cugat E, et al. Effect of venovenous bypass on perioperative renal function in liver transplantation: Results of a randomized, controlled trial. Hepatology 1996; 23: 1418 – 1428.
dc.identifier.citedreferenceZacharias M, Mugawar M, Herbison GP, et al. Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev 2013; 9: CD003590.
dc.identifier.citedreferenceO’Leary JG, Levitsky J, Wong F, Nadim MK, Charlton M, Kim WR. Protecting the kidney in liver transplant candidates: Practice‐based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant 2016; doi: 10.1111/ajt.13790.
dc.identifier.citedreferenceBelcher JM, Garcia‐Tsao G, Sanyal AJ, et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol 2014; 9: 1857 – 1867.
dc.identifier.citedreferenceLevitsky J, Baker TB, Jie C, et al. Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology 2014; 60: 2017 – 2026.
dc.identifier.citedreferenceWagener G, Minhaz M, Mattis FA, Kim M, Emond JC, Lee HT. Urinary neutrophil gelatinase‐associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant 2011; 26: 1717 – 1723.
dc.identifier.citedreferenceSirota JC, Walcher A, Faubel S, et al. Urine IL‐18, NGAL, IL‐8 and serum IL‐8 are biomarkers of acute kidney injury following liver transplantation. BMC Nephrol 2013; 14: 17.
dc.identifier.citedreferenceGonwa TA, Mai ML, Melton LB, et al. End‐stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin‐based immunotherapy: Risk of development and treatment. Transplantation 2001; 72: 1934 – 1939.
dc.identifier.citedreferenceGonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: Where will MELD lead us? Am J Transplant 2006; 6: 2651 – 2659.
dc.identifier.citedreferenceRemuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13: 261 – 272.
dc.identifier.citedreferenceShindoh J, Sugawara Y, Akamatsu N, et al. Thrombotic microangiopathy after living‐donor liver transplantation. Am J Transplant 2012; 12: 728 – 736.
dc.identifier.citedreferenceVerbiest A, Pirenne J, Dierickx D. De novo thrombotic microangiopathy after non‐renal solid organ transplantation. Blood Rev 2014; 28: 269 – 279.
dc.identifier.citedreferenceUtsumi M, Umeda Y, Sadamori H, et al. Risk factors for acute renal injury in living donor liver transplantation: Evaluation of the RIFLE criteria. Transpl Int 2013; 26: 842 – 852.
dc.identifier.citedreferenceYoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low‐dose tacrolimus regimen versus a standard‐dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064 – 1072.
dc.identifier.citedreferenceNeuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced‐dose tacrolimus, and renal function in liver transplantation: The ‘ReSpECT’ study. Am J Transplant 2009; 9: 327 – 336.
dc.identifier.citedreferenceCalmus Y, Kamar N, Gugenheim J, et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation 2010; 89: 1504 – 1510.
dc.identifier.citedreferenceBoudjema K, Camus C, Saliba F, et al. Reduced‐dose tacrolimus with mycophenolate mofetil versus standard‐dose tacrolimus in liver transplantation: A randomized study. Am J Transplant 2011; 11: 965 – 976.
dc.identifier.citedreferenceKlintmalm GB, Feng S, Lake JR, et al. Belatacept‐based immunosuppression in de novo liver transplant recipients: 1‐year experience from a phase II randomized study. Am J Transplant 2014; 14: 1817 – 1827.
dc.identifier.citedreferenceAsrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced‐dose tacrolimus versus standard‐dose tacrolimus after liver transplantation: The 2000‐2003 phase II prospective randomized trial. Am J Transplant 2014; 14: 356 – 366.
dc.identifier.citedreferenceTeperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor‐free mycophenolate mofetil/sirolimus maintenance in liver transplantation: The randomized spare‐the‐nephron trial. Liver Transpl 2013; 19: 675 – 689.
dc.identifier.citedreferenceDe Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. Am J Transplant 2012; 12: 3008 – 3020.
dc.identifier.citedreferenceSaliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734 – 1745.
dc.identifier.citedreferenceFischer L, Saliba F, Kaiser GM, et al. Three‐year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow‐up results from a randomized, Multicenter Study. Transplantation 2015; 99: 1455 – 1462.
dc.identifier.citedreferenceFischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin‐inhibitors to everolimus after liver transplantation–PROTECT. Am J Transplant 2012; 12: 1855 – 1865.
dc.identifier.citedreferenceSterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3‐year results from a randomized trial in liver transplantation. Am J Transplant 2014; 14: 701 – 710.
dc.identifier.citedreferenceBeckebaum S, Klein CG, Sotiropoulos GC, et al. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: Clinical results of a prospective randomized study. Transpl Proc 2009; 41: 2567 – 2569.
dc.identifier.citedreferenceBilbao I, Salcedo M, Gomez MA, et al. Renal function improvement in liver transplant recipients after early everolimus conversion: a clinical practice cohort study in Spain. Liver Transpl 2015; 21: 1056 – 1065.
dc.identifier.citedreferenceCastroagudin JF, Molina E, Romero R, Otero E, Tome S, Varo E. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15: 1792 – 1797.
dc.identifier.citedreferenceDe Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262 – 1269.
dc.identifier.citedreferenceKornberg A, Kupper B, Thrum K, et al. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI‐related renal dysfunction. Dig Dis Sci 2011; 56: 244 – 251.
dc.identifier.citedreferencePageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12: 1755 – 1760.
dc.identifier.citedreferenceSaliba F, Dharancy S, Lorho R, et al. Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis. Liver Transpl 2011; 17: 905 – 913.
dc.identifier.citedreferenceSchlitt HJ, Jonas S, Ganten TM, et al. Effects of mycophenolate mofetil introduction in liver transplant patients: Results from an observational, non‐interventional, multicenter study (LOBSTER). Clin Transplant 2013; 27: 368 – 378.
dc.identifier.citedreferenceAbdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial. Am J Transplant 2012; 12: 694 – 705.
dc.identifier.citedreferenceGoralczyk AD, Bari N, Abu‐Ajaj W, et al. Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: A systematic review of randomized controlled trials. Am J Transplant 2012; 12: 2601 – 2607.
dc.identifier.citedreferenceSchmeding M, Kiessling A, Neuhaus R, et al. Mycophenolate mofetil monotherapy in liver transplantation: 5‐year follow‐up of a prospective randomized trial. Transplantation 2011; 92: 923 – 929.
dc.identifier.citedreferenceStewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357: 609 – 610.
dc.identifier.citedreferenceKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2012; 2013 ( Suppl 3 ): 1 – 150.
dc.identifier.citedreferenceKidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2012; Suppl 2: 337 – 414.
dc.identifier.citedreferenceKent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin‐converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18: 1959 – 1965.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt13765_am.pdf
Size:
265.6KB
Format:
PDF
View/Open
Name:
ajt13765.pdf
Size:
113.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.